Answers are grounded in this paper and cite their sources.
This mini-review explores innovative drug design using MCoTI-II cyclic peptide, highlighting its role in creating bioactive epitopes for therapeutics and diagnostics.
Naturally occurring cyclic peptides have emerged as intriguing and relevant scaffolds for next-generation drug design. Especially peptides from the highly constrained cyclotide family provide an exceptional opportunity for drug discovery, given their characteristic head-to-tail cyclic structure and cystine-knotted core that confer favourable pharmaceutical properties. As a result, Momordica cochinchinensis trypsin inhibitor II (MCoTI-II), a cyclic knottin peptide natural product of gấc fruit, has been the centre of various molecular engineering efforts. To target medicinally relevant proteins, surface-exposed loops of the mini-protein have been purposefully modified or entirely selected de novo to install bioactive epitopes. This mini-review aims to provide a succinct overview of recent studies on MCoTI-II-derived structures in inhibitor and diagnostic design. A variety of methods facilitate access to MCoTI-II-based next-generation therapeutics and diagnostics, including rational design, loop grafting and genetically encoded discovery platforms.
No takes yet. Share an insight, caveat, or question.
Ullrich et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: